Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
May 11, 2004Current Opinion in Neurology

Neutralizing antibodies to interferon beta: implications for the management of multiple sclerosis

View Full Paper
Ask AI
Bookmark
Share

Key result

Neutralizing antibodies reduce or abolish interferon-beta efficacy in up to ~20% of multiple sclerosis patients.

Population

Patients with multiple sclerosis treated with interferon-beta

Design

Review

Authors

ABAntonio Bertolotto

Discussion

Loading...

Member takes

Overview

May warrant antibody testing in non-responders; leaves open standardized assays and management strategies.

Structured PICO

P
Population
Patients with multiple sclerosis treated with interferon-beta
E
Exposure
Interferon-beta therapy
O
Outcome
Therapeutic efficacy and bioactivity of interferon-beta

Neutralizing antibodies to interferon-beta reduce its therapeutic efficacy in 10-20% of multiple sclerosis patients, highlighting the need for standardized assays and optimal management strategies.

Limitations

  • Quantification of antibodies using various biologic methods makes it difficult to compare among different laboratories, necessitating standardization of assay procedures.

Cite This Study

Antonio Bertolotto (2004) conducted a review in Multiple sclerosis. Neutralizing antibodies to interferon-beta was evaluated. Neutralizing antibodies to interferon-beta reduce or abolish the therapeutic efficacy of interferon-beta in 10-20% of patients with multiple sclerosis.

synapsesocial.com/papers/6aa8ea2bb7876cb3302c8264https://doi.org/10.1097/00019052-200406000-00002
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Neutralizing antibodies against IFN- in multiple sclerosis: antagonization of IFN- mediated suppression of MMPs2004 · 69 citations
  2. 2Incidence and significance of neutralizing antibodies to interferon beta-1a in multiple sclerosis1998 · 331 citations
  3. 3Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b2003 · 107 citations
  4. 4Intramuscular interferon beta‐1a for disease progression in relapsing multiple sclerosis1996 · 2,457 citations
  5. 5Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies1999 · 196 citations